Interview, Podcast
Come on out, the vacuum’s fine: SpaceX
The EconomistRosie Bloor, Jason Palmer, Oliver Morton, Jared Isaacman, Sarah Gillis, Anna Menon, Scott Petit, Natasha Loda, Adam Roberts, Lane Green
- SpaceX's Polaris Dawn mission successfully executed the first commercial spacewalk (EV1) on Thursday at approximately 10:15 GMT, featuring crew member Jared Isaacman exiting the Dragon capsule.
- The mission operates at a higher altitude than any human-crewed flight in over 60 years, utilizing a polar orbit that exposes astronauts to a distinct radiation profile compared to standard low-Earth orbits.
- Crew members Sarah Gillis, Anna Menon, and Scott Petit accompanied Isaacman, marking the first operational testing of new low-pressure spacesuits designed to mimic the conditions of high-altitude Everest climbs to prevent suit rigidity.
- The Dragon capsule was modified to function as a "tin can" without an airlock; the crew vented the entire cabin atmosphere to near-vacuum before opening the hatch to perform the extravehicular activity.
- Mission Commander Jared Isaacman, a billionaire and payment industry founder, has contracted SpaceX for three Polaris missions, with the third (Polaris 3) planned to test the Starship vehicle in the future.
- Analyst Oliver Morton notes the mission reflects an ideological drive toward private-sector-led space exploration, contrasting with the government-led Apollo era, though he acknowledges the significant engineering challenges overcome by SpaceX's design.
- Commercial elements of the mission included product testing for Doritos, specifically a space-formulated variant with less "gunky" cheese to prevent debris in the vacuum, alongside research into laser links for Starlink satellite communications.
- The flight's success positions SpaceX ahead of competitor Boeing, following a recent test failure of Boeing's Starliner capsule, potentially reinforcing SpaceX's brand dominance in commercial crewed spaceflight.
- Gene-editing therapies, such as Casgevy for sickle cell disease and beta thalassemia, offer potential lifetime cures by editing patient stem cells but currently cost upward of $3 million per treatment.
- Pharmaceutical companies justify high pricing through high development risks and production costs, though projections suggest US spending on gene therapies alone could reach $30 billion annually by 2031 for roughly 500,000 patients.
- Proposed financial innovations to improve access include subscription-based models for insurers (analogous to Netflix) and installment payment plans with reimbursement clauses if therapies fail.
- Health editor Natasha Loda warns that purely financial solutions may entrench high prices unless accompanied by regulatory signals and market incentives that mandate future price reductions and encourage competitive entry.
- Cost reductions are expected long-term due to increased competition, manufacturing efficiencies, and innovations by developing nations like China, Brazil, and India.
- The Economist's daily briefing app, Espresso, has introduced a free subscription tier for students aged 16 and older to increase global access to journalism and build future readership habits.
- New features in the app include AI-driven translation capabilities allowing users to toggle content between English, French, Mandarin, and other languages, and AI-generated voiceovers for video explainers.
- The app provides access to four full-length Economist articles daily, the "Intelligence" podcast, quizzes, crosswords, and a daily newsletter, all free of advertising for eligible users.
- Editor-in-Chief Jason Palmer clarified that the Espresso app remains a loss-leader strategy; core journalism operations continue to rely on a paid subscription model due to the high costs of global correspondent networks and editorial overhead.
- Credits for the episode list Chris Impey and Jack Gill as editors, John Joe Devlin as deputy editor, and a production team including Rory Galloway, Sarah Larniuk, William Warren, and others.